Gene Expression in Response to Exercise in Patients with Chronic Fatigue Syndrome: A Pilot Study by Andrew Keech et al.
ORIGINAL RESEARCH
published: 22 September 2016
doi: 10.3389/fphys.2016.00421
Frontiers in Physiology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 421
Edited by:
Elisabeth Lambert,











This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology
Received: 07 July 2016
Accepted: 06 September 2016
Published: 22 September 2016
Citation:
Keech A, Vollmer-Conna U, Barry BK
and Lloyd AR (2016) Gene Expression
in Response to Exercise in Patients
with Chronic Fatigue Syndrome: A
Pilot Study. Front. Physiol. 7:421.
doi: 10.3389/fphys.2016.00421
Gene Expression in Response to
Exercise in Patients with Chronic
Fatigue Syndrome: A Pilot Study
Andrew Keech 1*, Ute Vollmer-Conna 2, Benjamin K. Barry 1, 3 and Andrew R. Lloyd 4
1 School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia, 2 School of Psychiatry, University of
New South Wales, Sydney, NSW, Australia, 3Neuroscience Research Australia, Sydney, NSW, Australia, 4 Inflammation and
Infection Research Centre, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
Chronic fatigue syndrome (CFS) is a debilitating disorder of unknown pathogenesis,
characterized by fatigue, which is exacerbated after minimal exercise. We examined
the effect of a single bout of aerobic exercise on leucocyte mRNA expression of genes
putatively linked to exaggerated afferent signaling as an under-pinning of the fatigue
state. A carefully-characterized sample of patients with CFS (N = 10) and healthy
matched control participants (N = 12) were included. Participant ratings of fatigue and
other symptoms, as well as blood samples, were obtained at baseline, and five other
time-points up to 72 h after 25 min of moderate-intensity cycling exercise. Leucocyte
mRNA of 19 metabolite-sensing, adrenergic, immune, and neurotransmission genes
was examined using quantitative polymerase chain reaction. Patients with CFS reported
substantial fatigue, functional impairment, and poor sleep at baseline (all p < 0.02), and
exercise immediately induced worsened patients’ fatigue (effect size, ES = 1.17). There
were no significant changes in gene expression after exercise and patients did not differ
from control participants at any time point. Higher levels of expression of ficolin (FCN1)
and a purinergic receptor (P2RX4) in patients with CFS were found when all time points
were combined. Patients with CFS did not show significant exercise-induced changes in
leucocyte mRNA of 19 metabolite-sensing, adrenergic, immune and neurotransmission
genes despite a prominent exacerbation of fatigue.
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INTRODUCTION
Chronic fatigue syndrome (CFS) is a complex medical condition characterized by persistent,
often debilitating fatigue (Fukuda et al., 1994). The disorder is also characterized by a post-
exertional exacerbation of fatigue and symptoms, a phenomenon commonly termed “post-
exertional malaise.” The fatigue and related symptoms, as well as functional capacity often take
hours to days to return to baseline levels (Light et al., 2012; Keech et al., 2015).
It has been proposed that CFS results from a “sensitization” in neural pathways in the brain
leading to inappropriate interpretation of physiological signals, ultimately leading to the conscious
sensation of fatigue. These physiological signals may originate in the periphery, or from within the
brain (Nijs et al., 2012). Recent investigations utilizing physical exercise to analyse correlates of the
post-exertional exacerbation phenomenon have raised the possibility of a disturbance in afferent
signaling originating in skeletal muscle during exercise (Light et al., 2012; Meyer et al., 2013).
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Light et al. reported increased leucocyte gene expression
after moderate-intensity exercise in patients with CFS but
not in matched healthy control participants, specifically for
sensory (metabolite-detecting) receptors (e.g., ASIC3, P2RX4),
adrenergic receptors (e.g., α-2A, B1, B2), and immune (e.g., IL-
6, IL-10) genes (Light et al., 2012). These post-exercise changes in
gene expression correlated with the exacerbation in self-reported
fatigue and pain recorded in the 48 h following the exercise
challenge. Some of these sensory, adrenergic, and immune
receptors have previously been implicated in sensory neuron
signaling of muscle fatigue and pain in the mouse (Light et al.,
2008), hence the authors speculated that leucocytes may act as a
surrogate for comparable changes within the muscle.
This study investigated leucocyte gene expression,
representing functional pathways possibly associated with
the sensation of fatigue, in carefully matched participants with
CFS and healthy individuals before and after moderate-intensity
exercise. It was hypothesized that patients with CFS would
display differential induction of leucocyte gene expression
when compared to matched control participants at baseline,
and display further increases in gene expression following
exercise, correlating with the post-exertional exacerbation
of fatigue. By replicating many aspects of the methodology
previously applied by Light et al. (2012), especially the analysis
of the same genes found to be differentially expressed in
patients with CFS following exercise, this study would provide
an independent analysis with the added value of repeated
baseline measures, and an extended assessment period (up
to 72 h following exercise). Additional genes with potential
relevance to the sensation of fatigue were also included. These
included neuro-behavioral genes, such as those involved in
the serotonergic system (SLC6A4, MAOA), which have been
hypothesized to be associated with fatigue through its interaction
with hypothalamus-pituitary-adrenal (HPA) axis function
(Smith et al., 2006). Genes involved in complement activation
and the lectin pathway (FCN1, C4a) were also included, due to
preliminary evidence of altered expression in patients with CFS
following exercise challenge (Sorensen et al., 2009).
METHODS
A well-characterized sample of patients with CFS (N = 10) and
healthy matched control participants (N = 12) were assessed
multiple times before and after a moderate-intensity aerobic
exercise challenge. A full description of data regarding study
participant characteristics, exercise challenge performance, and
self-report assessment values has been previously published
(Keech et al., 2015). Patients were drawn from a specialist
tertiary care clinic for management of the disorder, having been
diagnosed by a specialist according to the international criteria
(Fukuda et al., 1994). As such, all patients had a relatively stable
pattern of symptoms and well managed mood and sleep-wake
cycle, and were deemed by their treating clinician to be able to
meet the physical demands of the exercise challenge. Patients
were excluded if takingmedications that influence hypothalamic-
pituitary axis function, autonomic nervous system function, or
cytokine levels (e.g., beta-blockers), or had a contraindication
to participation. Healthy control participants were recruited
from university staff and students by advertisement. Patients
and control groups were matched by age, sex, BMI, and self-
reported levels of physical activity (typical hours per week of at
least moderate intensity exercise). The study was approved by the
institutional Human Research Ethics Committee. All participants
provided informed, written consent.
The exercise challenge consisted of 25 min of moderate-
intensity (70% of age-predicted maximum heart rate; APMHR)
cycling. APMHR was determined using a standard formula
[208 − (0.7 ∗ age)] (Tanaka et al., 2001). Participants rode on
a cycle ergometer (Monark 828E, Sweden) with cadence set at
50 revolutions per minute. The protocol started at 50 watts and
workload increased incrementally during the first 5 min of the
session until the target heart rate was reached. Workload was
regularly adjusted to maintain a heart-rate range of±3 beats/min
of the target. Participants wore a heart rate monitor and a mask
connected to a metabolic cart (open-circuit indirect calorimetry
system; Medgraphics Ultima CPX, Minnesota, USA) to allow for
continuous measurement of heart rate and gas exchange values.
RPE was obtained using the numeric, unmodified (6–20) Borg
scale (Borg, 1982), and was recorded every 5 min during the
session.
Baseline assessments were conducted 24 h before the challenge
and again immediately prior to the challenge. Post-exercise
assessments were conducted immediately following challenge
(post-0) and again at 1, 4, 24, and 72 h after the exercise bout. All
exercise challenges were conducted in the morning. Participants
attended the lab for the exercise session and the assessments
conducted on that day; all other assessments were performed at
the participant’s home to minimize the effect of travel-induced
fatigue in the patients. Participants rested in the lab for the first
hour following the exercise session, and were asked to maintain
normal daily routine for the entirety of the assessment period
(plus the 24 h leading in to the initial assessment). Participants
were also asked to abstain from caffeine or alcohol consumption
for 4 h prior to the assessments and in the lead-up to sleep each
night.
Participants were assessed for measures of gene expression in
association with the self-report of fatigue, using the Fatigue and
Energy Scale (FES; Keech et al., 2015). Physical symptoms, sleep
quality, and the level of functional impairment were obtained
at the initial baseline assessment via the SOMA sub-scale of
the Somatic and Psychological HEalth REport (SPHERE), the
Pittsburgh Sleep Quality Index (PSQI), and the Brief Disability
Questionnaire (BDQ), respectively (Buysse et al., 1989; Von Korff
et al., 1996; Hickie et al., 2001).
Gene Expression
Blood samples were collected in acid-citrate dextran (ACD)
tubes and processed within 4 h of sampling. Peripheral blood
mononuclear cells (PBMCs) was separated (Lymphoprep; AXIS-
SHIELD, Norway), and then lysed in Tri Reagent (Sigma, USA)
and immediately stored at −80◦C. RNA was extracted using
standard procedures (i.e., PBMCs were thawed and resuspended,
cells lysed with Trizol and separated using chloroform, the
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extracted RNA was precipitated with isopropanol, washed with
ethanol and resuspended in DEPC water). RNA integrity was
confirmed by Agilent 2100 bioanalyser (Agilent Technologies,
Germany) with a mean RNA integrity number (RIN) of 9.4
(range 8.2–10). cDNA libraries were synthesized using the ABI
High Capacity cDNA Archive kit (Applied Biosystems, Inc.,
USA) and stored at−20◦C until analysis. Samples were analyzed
using a quantitative, real-time PCR system (7900HT, Applied
Biosystems, Inc.) using ABI TaqMan Master Mix (Applied
Biosystems, Inc.). Master mix and primer probe solutions and
template solutions were separately loaded onto 96-well plates
before centrifugation to remove any air bubbles. Each sample
was run in duplicate with standards run in quadruplicate. Primer
probes (all from TaqMan Gene Expression Assays; Applied
Biosystems, Inc.) were as follows: ASIC3 (Hs00245097_m1);
P2RX4 (Hs00602442_m1); P2RX5 (Hs00531938_m1); P2RX7
(Hs00175721_m1); TRPV1 (Hs00218912_m1); adrenergic
α-2A (Hs00265081_s1); adrenergic β-1 (Hs02330048_s1);
adrenergic β-2 (Hs00240532_s1); COMT (Hs00241349_m1);
IL-6 (Hs00985639_m1); IL-10 (Hs00961622_m1);
IL-1β (Hs01555410_m1); IFN-γ (Hs00989291_m1);
FCN1 (Hs00157572_m1); MAOA (Hs00165140_m1);
MASP2 (Hs00198244_m1); NPY (Hs00173470_m1);
TLR4 (Hs01060206_m1); CD14 (Hs00169122_g1); PRF1
(Hs00169473_m1); SLC6A4 (Hs00169010_m1); LTA (TNF-α
superfamily) (Hs00236874_m1); C4a/C4b (Hs00246758_m1)
and the control probe 18-S (Hs99999901_s1).
Real-time PCR results were analyzed with SDS 2.2 Software
andData Assist v.3 (both Applied Biosystems, Inc.) and inspected
for errors in processing (e.g., loading errors, robot errors,
threshold errors). Data were analyzed according to the ddCT
method described in ABI User Bulletin#2 (Applied Biosystems,
Inc.). The maximum acceptable CT (threshold cycle) value was
set at 38. Genes were excluded from analysis if CT values were
greater than 38 for greater than 30% of all samples; this was
the case for three genes (NPY; MASP2; adrenergic α-2A). The
maximum CT value (i.e., 38) was included in calculations for all
other data points.Within participant datasets and their replicates,
outlier values were determined as those at least 2.5 SD outside
the group mean and at least four-fold different from values
obtained at adjacent time-points for that participant. These
criteria identified 13 outlier ddCT values (out of 2375 total
values); these were replaced by the cut-off criteria (group mean
± 2.5 SD). Other missing values (7 out of 2375 total values) were
replaced by the group mean for the difference between adjacent
time-points added to the individual’s previous time-point value.
Statistical Analysis
All analyses were performed using SPSS v20.0 (SPSS Inc.,
Chicago, IL). Statistical analysis of gene expression involved
analysis of ddCT values for each gene (relative to the reference
gene) at each assessment-point. In this process, ddCT values were
log (10) transformed to allow for parametric statistical analysis.
The baseline value of measures of gene expression was taken as
the mean of two pre-exercise assessments. Post-exercise values
for each gene expression measure were normalized relative to
the same participant’s baseline levels, allowing for analysis of fold
change. For two genes (IL-1β and PRF1), the log transformation
created a combination of negative and positive values, which
would not allow for analysis of fold change; in both instances,
a constant value of 1 was added to all raw ddCT values for each
gene.
Data were tested for normality using the Shapiro-Wilkes Test.
Independent t-tests were used to assess for group differences
in participant characteristics, self-reported fatigue and symptom
measures, baseline levels of gene expression (using the ddCT
values), and exercise challenge performance; a Chi-square test
assessed sex distribution. Non-normally distributed data were
analyzed using the Mann-Whitney test. Exploratory analysis of
gene expression and fatigue measures was conducted via 2-
way repeated measures ANOVA (2 groups × 6 time-points),
and a multivariate repeated-measures MANOVA was applied
to analyse across gene categories (metabolic-sensing; adrenergic;
immune; neurotransmission). Paired samples t-tests were applied
as follow-up tests to assess within group changes for all repeated
measures compared to baseline, and effect sizes were calculated
using Cohen’s d. Group comparisons of post-exercise gene
expression were also run on the mean fold change from baseline
for all post-exercise time-points combined, and correlation
analyses (Pearson’s r) sought two-tailed bivariate associations
between this measure for each gene and the severity of self-
reported fatigue after exercise (Area Under Curve, as determined
from sum of change from baseline values for all post-exercise
time-points combined). Significance for statistical measures
involving gene expression data was set at p < 0.01, given the
number of gene expression parameters analyzed (i.e., 19 genes
per time-point). Data in text and tables are presented as mean
± standard deviation (SD); figures are presented as mean ±
standard error of the mean (SEM).
In the gene expression dataset, the data from the control
probe, 18-S (Hs99999901_s1) showed an unsatisfactorily high
coefficient of variance (CV) across samples (7.4%) and a
significant difference in cycle counts (CT values) between groups
(p < 0.001). Accordingly, CD14 was chosen as the reference
gene based on the lack of significant variation within-participants
over time (CV 3.4%), and closely comparable CT values between
groups (25.7 ± 0.9 for control participants and 25.6 ± 0.9 for
patients; p = 0.66). This gene has similarly been reported to be
invariant in patients with CFS, including after exercise (Light
et al., 2012; Meyer et al., 2013). All gene expression levels were
normalized relative to this control probe.
RESULTS
In brief, the study involved patients with CFS (N = 10, 6 female;
41.4 ± 8.4 years) and healthy control participants (CON: N =
12, 8 female; 34.1 ± 10.2 years) of comparable body mass index
(BMI) (CFS: 22.1± 3.2; CON: 24.1± 1.9; p= 0.09) and physical
activity levels (CFS: 1.2 ± 1.0 h/week; CON: 1.7 ± 1.4 h/week;
p= 0.39). Consistent with the diagnosis of CFS, patients reported
higher baseline levels of fatigue (FES) (CFS: 5.1 ± 1.1; CON: 0.4
± 0.7; p < 0.001), more physical symptoms (SOMA) (CFS: 6.6
± 2.4; CON: 0.7 ± 1.1; p < 0.001), lower quality of night-time
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sleep (PSQI) (CFS: 7.6 ± 2.2; CON: 2.9 ± 2.1; p < 0.001)
and less physical function (BDQ) (CFS: 13.1 ± 4.4; CON: 0.2
± 0.4; p < 0.001) in the baseline assessment than control
participants. No participant reported performing any strenuous
exercise or cognitive activity in the 24 h leading in to the initial
baseline assessment, or during the entire assessment period
(other than the exercise challenge). All participants completed
the full duration of the exercise challenge without any breaks
and there were no significant between-group differences in most
indices of exercise performance, however patients consistently
reported higher ratings of perceived exertion (RPE) (mean values
drawn from the last 20min of exercise: CFS: 15.3 ± 1.8; CON:
11.5± 1.3; p< 0.001).
In response to exercise, patients with CFS reported higher
levels of fatigue than the CON group at each assessment-point
after exercise (all p< 0.001). In control participants, mean ratings
of fatigue on the FES over the assessment period never exceeded
1 (described on the scale as just noticeable) out of 10, and exercise
did not induce any significant increase in fatigue compared to
baseline. By contrast in patients with CFS, ratings of fatigue
increased significantly immediately following exercise (7.1± 1.6;
ES = 1.53) and raised levels of fatigue were maintained for 24 h
after the trial (6.6 ± 1.9) (both p ≤ 0.025). These scores reflect
a change in mean fatigue severity from moderate levels before
exercise to high levels after exercise.
Gene Expression
One control participant did not provide blood samples (CON:
N = 11). No significant between-group differences in mRNA
levels (ddCT values) were seen at baseline or in the mean post-
exercise fold change levels for any of the 19 gene receptors
of interest (all p > 0.03; Table 1). MANOVA analysis of
genes grouped according to functional pathway also showed no
significant group differences at baseline or following exercise
(all p > 0.05; Table 1). There was a main effect between groups
across all assessment points (i.e., combining before and after
exercise values) for 2 genes: FCN1 (p = 0.009) and P2RX4 (p
= 0.002; Figure 1). There was no significant effect of exercise
on any gene for the patient group, or a group × time effect for
any gene. Figure 2 shows the mean fold change in ddCT values
from baseline for each of the gene receptors for each of the
assessment-points after exercise. The range of fold change from
baseline for the CFS group was 0.70 (SLC6A4 at post-4 h) to 2.39
(adrenergic β-1 at post-24 h); and for the CON group, 0.55 (IL-
10 at post-72 h) to 2.08 (adrenergic β-1 at post-72 h). Baseline
levels of fatigue did not correlate with any baseline measure of
gene expression, and post-exercise change in fatigue levels did not
correlate with the post-exercise mean fold change in the level of
expression (in relation to baseline) for any gene.
DISCUSSION
This study analyzed gene expression before and after
moderate-intensity aerobic exercise in a well-characterized
patient group with CFS and healthy control participants.
The prominent exacerbation of fatigue following exercise
was not accompanied by any significant abnormalities in
expression of the metabolite-sensing, adrenergic, immune,
or neurotransmission genes in the patient group, either in
comparison to healthy control participants or within the patient
group following exercise. There was also no difference between
the patient group and the control group in baseline levels of
gene expression prior to the exercise bout. These findings do
not replicate the closely comparable study by Light et al., which
noted prominent changes in expression of many of these genes
following exercise in patients with CFS (Light et al., 2012).
However, the gene expression data are generally consistent with
the findings by Meyer et al. who did not observe differential
expression between patients and control participants for 12 of
the 14 genes studied, with the exception of adrenergic α-2A
and NR3C1 (a glucocorticoid receptor), neither of which
was studied here (Meyer et al., 2013). Each of these prior
studies applied an exercise challenge to induce post-exertional
exacerbation of symptoms in patients with CFS, and utilized
comparable gene expression testing and statistical analysis
procedures.
Despite similar methodologies, there are some key differences
between these three studies. Firstly, the Light et al. dataset
included a subset of patients with severe functional disability,
characterized as being predominantly house- or bed-bound
with minimal activity tolerance and dependent upon others
for activities of daily living (Light et al., 2012). This subset
of patients showed significant increases in gene expression
following exercise, in contrast to the relatively mild increases
in gene expression seen in the rest of the patient group,
who were reporting up to moderate disability. Our study
did not include any patients with severe functional disability,
and so could not examine the possibility of disordered gene
expression following exercise for participants with more severe
CFS. Although the patient group reported here are more typical
of the illness severity and functional capacity of patients with
CFS, further studies to test more severely affected patients
are warranted—to consider whether the reported association
relates to the disease process itself, or rather reflects secondary
pathophysiological changes associated with prolonged illness and
inactivity. Secondly, in contrast to the other studies, Meyer
et al. applied a maximal aerobic capacity test, which is a
more physically intense but shorter duration exercise challenge
(Meyer et al., 2013). While it is plausible that the different
exercise intensity may have differentially affected gene expression
patterns following exercise, the time-course and severity of
patients’ symptom exacerbation following exercise was similar
across all studies. Thirdly, our study differed in the choice
of the reference gene chosen for normalization of the gene
expression dataset. Light et al. reported that TF2B had less
intrinsic variation than other housekeeping candidates, had an
expression level that was similar to the genes of interest, and
did not vary with the exercise protocol (Light et al., 2012).
By contrast, the putative reference gene initially selected in
our study (18-S) displayed transcription levels which varied
significantly between individuals and were not distributed
normally. An alternative reference gene with very limited within-
subject and between-subject variation (CD14) was therefore
chosen.
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TABLE 1 | Means (±SD), t-test, effect size and MANOVA results for baseline ddCT values for mRNAs relative to the reference gene, and post-exercise
expression fold change values relative to baseline, from patients with CFS (N = 10) and control participants (N = 11).
Gene receptor Baseline values Post-exercise values
CFS Controls p d CFS Controls p d
Metabolite-detecting MANOVA 0.11 0.66 MANOVA 0.52 −0.23
ASIC3 0.0090±0.0079 0.0047± 0.0019 0.17 0.75 1.16± 0.66 1.41± 0.8 0.42 −0.34
P2RX4 0.1597±0.0614 0.1090± 0.0385 0.03 0.99 1.07± 0.35 1.07± 0.28 0.99 0
P2RX5 0.2149±0.1559 0.195± 0.1226 0.71 0.14 1.05± 0.36 1.15± 0.38 0.55 −0.27
P2RX7 0.0416±0.0169 0.0302± 0.0109 0.08 0.80 1.07± 0.32 1.13± 0.28 0.64 −0.20
TRPV1 0.0099±0.0054 0.007± 0.0033 0.16 0.65 1.08± 0.34 1.25± 0.58 0.76 −0.35
Adrenergic MANOVA 0.21 0.55 MANOVA 0.33 −0.26
β-1 0.0053±0.0046 0.0033± 0.0022 0.22 0.55 1.11± 0.61 1.59± 0.99 0.31 −0.58
β-2 0.2343±0.1427 0.1724± 0.0693 0.22 0.55 1.22± 0.33 1.2± 0.23 0.86 0.07
Immune MANOVA 0.56 0.53 MANOVA 0.18 0.07
C4a/C4b 0.0093±0.0057 0.0062± 0.0025 0.23 0.70 1.14± 0.46 1.19± 0.33 0.74 −0.12
FCN1 3.9453±1.1122 3.1295± 0.6846 0.06 0.88 1.09± 0.19 0.98± 0.22 0.26 0.54
IFN-γ 0.0182±0.0199 0.0103± 0.0066 0.51 0.53 1.02± 0.41 1.0± 0.44 0.92 0.04
IL-6 0.0071±0.009 0.0051± 0.0037 0.61 0.29 1.21± 0.58 1.06± 0.52 0.54 0.27
IL-10 0.0106±0.0096 0.0086± 0.0062 0.99 0.25 1.23± 0.37 0.96± 0.55 0.21 0.58
IL-1β 0.3893±0.332 0.2851± 0.2585 0.31 0.35 1.12± 0.49 1.08± 0.5 0.81 0.08
LTA 0.0242±0.0243 0.0128± 0.0073 0.28 0.64 0.88± 0.39 1.18± 0.29 0.06 −0.87
PRF1 0.5247±0.298 0.3817± 0.1923 0.22 0.57 1.08± 0.31 1.16± 0.34 0.61 −0.24
TLR-4 0.0237±0.0081 0.0195± 0.0065 0.21 0.57 1.08± 0.33 0.98± 0.23 0.46 0.35
Neurotransmission MANOVA 0.37 0.19 MANOVA 0.46 −0.17
COMT 0.2918±0.1653 0.1776± 0.107 0.04 0.82 0.87± 0.43 1.09± 0.43 0.26 −0.51
MAOA 0.0013±0.0017 0.0019± 0.0016 0.11 −0.36 1.07± 0.43 0.91± 0.55 0.46 0.32
SLC6A4 0.005±0.0046 0.0045± 0.0049 0.76 0.11 0.87± 0.53 1.03± 0.4 0.44 −0.34
ASIC3, acid-sensing ion channel; P2RX4, purinergic type 2RX4 receptor; P2RX5, purinergic type 2RX5 receptor; P2RX7, purinergic type 2RX7 receptor; TRPV1, transient receptor
potential vanilloid type 1; COMT, catechol-O-methyltransferase; C4a/C4b, Complement C4-a/Complement C4b; FCN1, ficolin-1; IFN-γ , interferon-γ ; IL-6, interleukin-6; IL-10, interleukin-
10; IL-1β, interleukin-1β; LTA, lymphotoxin-α (TNF-β superfamily); PRF1, perforin 1; TLR4, toll-like receptor 4; MAOA, monoamine oxidase-A; SLC6A4, serotonin transporter.
Baseline values were the average of the two assessment time-points prior to exercise. Post-exercise analysis includes the mean change in expression, in relation to baseline levels
(= 1.00), across all post-exercise assessment time-points.
FIGURE 1 | Mean (SEM) gene expression (ddCT, relative to the reference gene) for (A) FCN1 and (B) P2RX4 before and following moderate intensity
aerobic exercise in patients with CFS (N = 10) and matched healthy control participants (N = 11).
The gene expression data did reveal consistently higher levels
of expression of ficolin (FCN1) and one of the purinergic
receptors (P2RX4) in patients with CFS, but which were not
differentially expressed after exercise. These two genes reflect
different biological pathways [FCN1—immune (lectin pathway
of complement activation); P2RX4—energy metabolism (via
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FIGURE 2 | Changes in leucocyte gene expression following moderate intensity aerobic exercise in (A) patients with CFS (N = 10) and (B) matched
healthy control participants (N = 11). Data for each gene at each time-point are depicted as mean (SEM) fold increases from pre-exercise baseline. Graphs are
plotted on log2 scale.
ATP)] and there is no clear biological link between the two.
With regard to P2RX4, Light et al. observed raised levels of
expression following exercise (as reflected in the AUC values) but
not at baseline (Light et al., 2012), while Meyer et al. observed
no abnormal expression in P2RX4 in patients at baseline or after
exercise (Meyer et al., 2013). Neither previously published gene
expression study measured ficolin, however an earlier pilot study
by Sorensen et al. reported raised levels (>two-fold) of ficolin
and C4a expression in at least 4 out of 8 patients with CFS
at an assessment time-point 1 h following exercise (Sorensen
et al., 2009). It should be noted that Sorensen et al. found
that ficolin was not differentially expressed at baseline or 6 h
following exercise, and the data reported here did not reveal any
abnormality in patients’ C4a expression. It should be noted that
as previous reports indicate FCN levels vary in monocytic sub-
populations (Frankenberger et al., 2008), the choice of CD14 as a
normalization transcript may have influenced this analysis.
Of these two genes, P2RX4 is the most likely candidate
for further investigation in relation to the pathophysiology
of CFS and the “central sensitization” paradigm. P2RX4 has
recently been implicated as a key factor in driving neuropathic
pain, with raised levels of de novo expression within the CNS
signifying a specific underlying microglia response phenotype
which is critical for the pathogenesis of pain hypersensitivity
caused by injury to peripheral nerves (Beggs et al., 2012;
Tsuda et al., 2013). A recent preliminary finding of neuro-
inflammation, detected using positron emission tomography
(PET), in patients with CFS may likewise suggest microglial
involvement in the pathophysiology (Nakatomi et al., 2014). In
general, ddCT values in the present study reflect low levels of
mRNA expression, which varied very little within, or between,
participants. Accordingly, the biological significance of the gene
expression differences associated with CFS, even if detectable
statistically, is questionable.
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Strengths and Limitations
This study analyzed a well-characterized patient group with
stable mood and optimized sleep-wake cycle patterns, and a
control group matched for physical activity levels, and applied
two baseline measures and multiple repeated measures post-
exercise for each participant. However, a relatively small sample
size and the absence of patients on themore severe end of the CFS
spectrum limits the ability to draw more definitive conclusions,
while the ability to compare these findings with those previously
reported by Light et al. and Meyer et al. (Light et al., 2012; Meyer
et al., 2013) is limited by the application of a different reference
gene. In addition, while expression of genes on leucocytes may
plausibly be used as a surrogate of activity of the same genes
within the nervous system, there are no published data directly
supporting this assertion. Therefore, interpretation of leucocyte
gene expression data with respect to nervous system activity
should be performed cautiously.
CONCLUSION
A bout of moderate-intensity aerobic exercise induced a
sustained exacerbation of fatigue in patients with CFS, but
was not accompanied by corresponding changes in leucocyte
gene expression for a selection of genes involved in metabolite-
sensing, adrenergic, immune, or neurotransmission pathways.
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